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Abstract
Background: Most patients with relapsing-remitting multiple sclerosis (RRMS) eventually enter a secondary progressive
(SPMS) phase, characterized by increasing neurological disability. The mechanisms underlying transition to SPMS are
unknown and effective treatments and biomarkers are lacking. Vascular endothelial growth factor-A (VEGF-A) is an
angiogenic factor with neuroprotective effects that has been associated with neurodegenerative diseases. SPMS has a
prominent neurodegenerative facet and we investigated a possible role for VEGF-A during transition from RRMS to SPMS.
Methodology/Principal Findings: VEGF-A mRNA expression in peripheral blood mononuclear (PBMC) and cerebrospinal
fluid (CSF) cells from RRMS (n=128), SPMS (n=55) and controls (n=116) were analyzed using real time PCR. We
demonstrate reduced expression of VEGF-A mRNA in MS CSF cells compared to controls (p,0.001) irrespective of disease
course and expression levels are restored by natalizumab treatment(p,0.001). VEGF-A was primarily expressed in
monocytes and our CSF findings in part may be explained by effects on relative monocyte proportions. However, VEGF-A
mRNA expression was also down regulated in the peripheral compartment of SPMS (p,0.001), despite unchanged
monocyte counts, demonstrating a particular phenotype differentiating SPMS from RRMS and controls. A possible
association of allelic variability in the VEGF-A gene to risk of MS was also studied by genotyping for six single nucleotide
polymorphisms (SNPs) in MS (n=1114) and controls (n=1234), which, however, did not demonstrate any significant
association between VEGF-A alleles and risk of MS.
Conclusions/Significance: Expression of VEGF-A in CSF cells is reduced in MS patients compared to controls irrespective of
disease course. In addition, SPMS patients display reduced VEGF-A mRNA expression in PBMC, which distinguish them from
RRMS and controls. This indicates a possible role for VEGF-A in the mechanisms regulating transition to SPMS. Decreased
levels of PBMC VEGF-A mRNA expression should be further evaluated as a biomarker for SPMS.
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Introduction
Multiple Sclerosis (MS) is a chronic inflammatory demyelinating
disease of the central nervous system (CNS). A majority of patients
initially display a relapsing-remitting disease course (RRMS),
characterized by inflammatory demyelinating attacks, axonal
injury and varying degree of repair [1]. However, most RRMS
patients with time enter a secondary progressive phase (SPMS),
with failure of repair mechanisms leading to gradual neurodegen-
eration and a continuous accumulation of disability [1]. The
strongest predictive factors favoring an earlier transition to a
progressive disease course are efferent symptoms and lack of
complete remission of the onset bout [2].The neurodegenerative
component in progressive MS is more prominent and disease
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breakthrough RRMS disease, have only limited effects in SPMS
[3,4,5].Very little is known about the mechanisms underlying the
transition to progressive MS disease and the diagnosis of a
progressive disease course is made solely on clinical grounds, since
reliable supporting laboratory or neuroradiological tests are
lacking [6]. In clinical practice it is often difficult to determine
when the progressive disease starts until it has already been going
on for a longer time, which makes it complicated to use as an
outcome in clinical trials and also poses a clinical problem for
treatment decisions.
A number of potential biomarkers for monitoring of MS disease
course, response to therapies and prediction of disability have been
studied, some of them with promising results [7,8]. However, there
is a scarcity of candidates evaluated as biomarkers for SPMS,
although a recent study demonstrated that levels of complement
factor H is elevated in SPMS compared to RRMS [9]. Vascular
endothelial growth factor A (VEGF-A) is an angiogenic and pro-
inflammatory factor with neuroprotective effects on neuronal and
glial cells that also stimulates proliferation and survival of neural
stem cells [10,11]. Studies on the neurodegenerative diseases
amyotrophic lateral sclerosis (ALS) and Alzheimer’s disease (AD)
have suggested a role for VEGF-A in the pathogenesis of these
diseases and a genetic association between VEGF-A variants and
these diseases has been demonstrated [12,13,14,15,16,17,18].
Results from a few smaller studies have also indicated a role for
VEGF-A in MS [19,20,21,22,23]. We previously observed
decreased levels of VEGF-A in cerebrospinal fluid (CSF) cells
from a small group of MS patients compared to controls [22].The
objective of this study was to determine VEGF-A expression
profiles in CSF and peripheral blood in a large cohort of well
characterized MS patients and relate this to different disease
measures. In addition, we have investigated if genetic variability in
the VEGF-A gene is associated to risk of MS.
Methods
Ethics Statement
The study was approved by the regional ethical committee,
‘‘Regionala etikpro ¨vningsna ¨mnden i Stockholm, EPN’’ and
written informed consent was obtained from all patients.
Patients
All CSF- and peripheral blood mononuclear cells (PBMC)
samples were obtained from our in-house biobank containing
samples collected, during routine neurological diagnostic work up
or during clinical follow-up, from 2001 to 2009. Samples from
natalizumab treated patients were collected before and after one
year of treatment for study purposes. Demographic data of the
patients included in the expression studies are described in Table
S1. Two patient cohorts were used for VEGF-A expression
analysis; study group A composed of RRMS (n=63), SPMS (n=35)
and controls with other non-inflammatory neurological diseases
(OND) (n=68), and study group B used for replication with RRMS
(n=65), SPMS (n=20) and OND (n=48). All MS patients
fulfilled the McDonald criteria [24]. Classification and scoring of
MS patients was assessed by a trained neurologist. For RRMS, a
relapse was defined as an increase with $1 point on the expanded
disability status scale (EDSS), with duration of at least one week
before sampling, where systemic infection had been ruled out.
Remission was defined as a stable clinical status .3 months prior
to sampling. SPMS was defined as an initial relapsing-remitting
disease course followed by more than 12 months of continuous
worsening of neurological function ($0.5 EDSS point) not
explained by relapses. At time of sampling, 14 RRMS patients
were on immunomodulatory treatment including IFN-b1a (n=8),
IFN-b1b (n=3), glatiramer acetate (n=2) and intravenous
immunoglobulins (n=1), and 2 OND patients were on low doses
of oral corticosteroids. Magnetic resonance imaging (MRI) data
obtained within 2 months of sampling was available in 80 cases.
Routine MRI examinations and determination of oligoclonal
bands and IgG index in CSF and serum were performed as
described previously [25]. The OND control groups included
patients with diagnoses listed in Table S2.
Sample preparation and mRNA expression analysis
CSF cells were collected and processed as previously described
[26]. Peripheral blood was collected in sodium citrate-containing
cell preparation tubes (Vacutainer CPT; BD Biosciences, San Jose,
California, USA) and EDTA tubes. PBMC were separated by
density gradient centrifugation and cells from the interphase were
collected and washed twice with Dulbeccos’s PBS. Cell pellets
were frozen on dry ice and stored at 280uC until analysis. Total
RNA was extracted and reverse transcribed as previously
described [26]. Two RT-PCR expression assays were used; The
SYBR-Green-based protocol was used for analysis on study group
A and the TaqMan gene expression assay was used for study
group B. A BioRad iQ5 iCycler Detection System (BioRad
Laboratories, Ltd) was used for both protocols. A three-step PCR
protocol (95uC for 10 min, followed by 40 cycles of 95uC for
15 sec, 60uC for 30 sec and 72uC for 30 sec) with SYBR-Green-
based primers (sequences available upon request) and a two-step
PCR protocol (95uC for 10 min, followed by 40 cycles of 95uC for
15 sec. and 60uC for 1 min), with FAM fluorophore was used for
the TaqMan gene expression assay (ordered online from https://
products.appliedbiosystems.com). The TaqMan gene expression
assay ID for different targets were: GAPDH (Assay ID:
Hs99999905_ml and VEGF-A (Assay ID: Hs00173626_ml.
Relative quantification of mRNA was performed using the
standard curve method using GAPDH as endogenous control.
PCR efficiencies .90% were accepted. Analytical sensitivity
performance characteristics were determined using ten-fold serial
dilutions of pooled cDNA from twenty cases and controls as
standard curve, and GAPDH as an internal endogenous control
for the housekeeping gene. Intra-run replicates of serially diluted
cDNA over the linear range of the assay demonstrated minimal
variation in cycle threshold (Ct) values with a variation of ,0.2 Ct,
approximately corresponding to ,5% variability in absolute
levels.
Flow cytometry
PBMC were isolated (as described above) from freshly collected
blood samples obtained during clinical follow-up from five
treatment naı ¨ve RRMS patients (2 females, 3 males; mean age
35) and nine RRMS patients treated with 2–24 infusions of
natalizumab (4 females, 5 males; mean age 35 years). Cell
populations sorted from PBMC included pure CD3
+CD4
+ (helper
T cells), CD3
+CD4
2 (mainly cytotoxic T cells), CD19
+ (B cells)
and CD14
+ (monocytes) in the treatment naı ¨ve MS patient group
and CD3
+CD4
+ (helper T cells), CD3
+CD8
+ (cytotoxic T cells),
CD3
+CD4
+CD25
high (regulatory T cells; Treg), CD3
2C304
+
(plasmacytoid dendritic cells; pDC) and monocyte gated cell
populations in the natalizumab treated group. Cell populations
were sorted from PBMC on a MoFlo high-speed cell sorter
(DakoCytomation, Glostrup, Denmark) after staining with fluor-
escently labeled Abs from BD Biosciences, (San Jose, CA) and
Miltenyi Biotec GmbH (Surrey, UK). After centrifugation, the cell
pellets were lysed and prepared for RNA preparation and cDNA
VEGF-A Is Downregulated in Progressive MS
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SYBR-Green based protocol as described above.
Genetic association study
A genetic association study was performed on 1114 Swedish
patients with a MS diagnosis according to either Poser [27] or
McDonald [24] (73% females, 27% males; mean age at sampling
53 years, IQR 22–91 years). The control group consisted of 1234
healthy blood donors (63% female and 37% male; mean age at
sampling 47 years, IQR 21–76 years). Blood was sampled
between 1987 and 2004 and genomic DNA was extracted from
whole blood using standard procedures. Genotyping was
performed with TaqMan SNP genotyping assay (Applied
Biosystems) according to the manufacturer’s instructions with
225 nM primer, 50 nM probe and 1 ng/ml genomic DNA in a
total reaction volume of 5 ml. Further details are available upon
request. Six SNPs tagging haplotype blocks across the entire
VEGF-A gene on chromosome 6p21.3 were selected with
Haploview using Tagger (r
2 threshold=0,8, LOD threshold for
multi marker test=3), (Table 1).
Statistical analysis
VEGF-A mRNA expression data in MS and controls were
analyzed with the non-parametric Kruskal-Wallis test. For
analysis of correlation between gender and VEGF-A level, the
two-way ANOVA test was used with Bonferroni’s post test.
Correlations between VEGF-A levels and quantitative clinical
measures (years of MS disease duration, EDSS, MSSS), age and
correlations between VEGF-A in CSF mononuclear cells and
PBMCs were analyzed with Spearman’s rank test and non-linear
regression for curve fit and the Kruskal-Wallis’ test for multiple
comparisons. The Mann-Whitney test for two-group comparison
was used to compare VEGF-A levels between groups with either
,9/$9 MRI lesions, presence/absence of oligoclonal bands and
normal/increased IgG-index. Analyses were carried out in
GraphPad Prism 3.0 (GraphPad, San Diego, CA). Association
analysis for risk of MS and single SNPs and haplotypes in VEGF-
A was performed with R 2.8.0 using the package SNPassoc [28]
and with Haploview 4.0. Power analysis was performed using
genetic Power Calculator with a estimated prevalence for MS of
0.001 and a multiplicative model and type 1 error=0.05 for allele
test [29].
Results
VEGF-A mRNA expression in PBMC and CSF cells
The relative expression of VEGF-A mRNA in CSF cells was
drastically reduced both in RRMS and SPMS compared to
controls as determined by SYBR-Green quantitative PCR in a first
set of patients (study group A). Thus, RRMS displayed a three-fold
and SPMS an eight-fold reduction of VEGF-A mRNA expression
compared to OND controls in CSF cells (Figure 1A). In contrast,
VEGF-A mRNA levels in PBMC were similar in RRMS and
controls, but significantly reduced in SPMS (Figure 1B). No
significant difference between RRMS in relapse and remission was
found in CSF cells or PBMC. Both the findings of a down
regulation of VEGF-A expression in CSF cells irrespective of
disease course and the down regulation in PBMC solely in SPMS
were corroborated in a separate set of patients (study group B) using
a probe-based TaqMan PCR protocol (Figure S1A, B). In
addition, there was a trend towards higher levels of VEGF-A
expression in PBMC from RRMS sampled during a relapse as
compared to patients in remission (Figure S1B).
Expression of VEGF-A in CSF cells or PBMC was not
correlated to any measures of disease severity (EDSS, MSSS,
disease duration), nor did the expression differ between groups
with or without more than nine T2 MRI lesions, or oligoclonal
bands and/or increased IgG index (data not shown). The
expression level of VEGF-A mRNA in CSF cells and PBMC
was positively correlated in the SPMS group in study group A
(R
2=0,17, p-value: 0.01612) and with borderline significance in
study group B (R
2=0,19, p-value 0,059). No significant correla-
tion between VEGF-A mRNA expression in CSF cells and PBMC
was observed in RRMS or in the control groups. In addition,
neither gender nor age correlated with VEGF-A expression in
PBMC or CSF cells (Figure S2).
Table 1. Association analysis for risk of MS and single SNPs and haplotypes in VEGF-A.
SNP Position Genotype frequencies Alleles MAF % GT HWE P-value P-value
MM/Mm/mm
f Association
Rs # Mb Controls MS major:minor Hap This All MS All Control Case Codominant
Map study model
Rs833060
a 43,843,127 712/424/71 616/337/71 G:T 70.0 76.6 96.5 91.3 0.0264 0.4704 0.0112 0.3894
Rs699947
b 43,844,367 333/598/311 274/493/255 A:C 47.8
c 51.0 98.3 91.2 0.0740 0.1922 0.2606 0.9986
Rs1570360
d 43,845,808 570/495/125 413/375/110 G:A -
e 67.6 91.4 80.1 0.0089 0.2525 0.0837 0.4114
Rs25648 43,846,955 567/280/25 682/290/28 C:T 82.3 82.0 82.3 89.2 0.2453 0.1864 0.7407 0.3346
Rs3025030 43,858,565 866/336/28 734/269/32 G:C 84.5 84.1 98.4 92.3 0.6415 0.5941 0.2486 0.4075
Rs10434 43,861,190 342/612/278 279/511/249 G:A 56.2 52.1 98.0 92.7 0.7083 0.9090 0.6196 0.7142
No genetic association was found between SNPs in the VEGF-A gene and overall risk for MS in 1114 MS (n=1114) healthy controls (n=1234).
aVEGF-A exon 1 starts at position 43,845,931. All positions according to NCBI SNP database.
bAlso denoted 22578C/A. The AA genotype has lower VEGF-A levels [45,46] and is associated with increased risk of amyotrophic lateral sclerosis in males [17] and
increased risk of Alzheimer’s disease [18].
cC is the major allele in HapMap. The frequency given in the table is for allele A.
dAlso denoted 21154G/A. A-allele and AA-genotype lowers VEGF-A levels [45,46].
eNo allele frequency data available in HapMap or dbSNP.
fM=Major, m=minor allel.
doi:10.1371/journal.pone.0019138.t001
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In sorted PBMC populations from treatment naı ¨ve MS patients,
expression of VEGF-A mRNA was found mainly in CD14
+
monocytes (Figure 2A). In a prior study we detected expression of
VEGF-A in mononuclear cell infiltrates in rats with experimental
autoimmune encephalomyelitis (EAE) [22], suggesting that
VEGF-A could potentially be expressed in T regulatory cells
and/or myelin-specific autoreactive T cells that are enriched in the
CNS of MS patients. We therefore took advantage of the
therapeutic effect of natalizumab, which blocks the transmigration
of lymphocytes across the blood-brain barrier resulting in
peripheral sequestration of encephalitogenic T cells [30]. VEGF-
A mRNA levels were determined in sorted PBMC from nine
patients treated with natalizumab. Again, levels of VEGF-A were
highest in monocytes and low or undetectable in the other
analyzed cell populations (Figure 2B). Thus, in PBMC, monocytes
constitute the major source of expression of VEGF-A, with some
expression also in B cells and CD8
+ T cells.
In order to exclude that reduced VEGF-A expression levels in
PBMC from SPMS patients could be explained by difference in
cellular composition, absolute and relative peripheral blood
monocyte numbers were determined as part of a complete
peripheral blood count in RRMS (n=53), SPMS (n=19) and
controls (n=58). This analysis did not reveal any discernible
differences in the absolute or relative number of peripheral blood
monocytes between the different groups (Table 2).
Effect of natalizumab on VEGF-A mRNA expression
In order to test if immunomodulatory treatment could alter the
expression of VEGF-A, we studied the effect of natalizumab
treatment in a set of RRMS patients. As monocytes express the
highest levels of VEGF-A, we also estimated the relative
proportion of monocytes by measuring the expression of the
monocyte cell marker CD14. VEGF-A and CD14 mRNA in CSF
cells and PBMC were determined in 19 RRMS patients (10
females, 9 males, mean age 40 years, IQR 33–49 years) prior to
initiation of natalizumab and again after 12 months of treatment.
There was a robust increase in CSF cell VEGF-A expression and a
more moderate increase of CD14 mRNA expression in CSF cells,
but no change in PBMC (Figure 3), suggesting both an effect on
cellular CSF composition and a relative increased in VEGF-A
expression.
Figure 1. Box-whisker plot of VEGF-A mRNA expression in CSF cells and peripheral blood mononuclear cells (PBMC). Relative VEGF-A
mRNA expression is reduced in CSF cells (A) in RRMS (n=34) and SPMS (n=32) compared to controls (OND; n=47), and in PBMC (B) from SPMS
(n=35) compared to RRMS (n=63) and OND (n=68). No significant difference between RRMS in relapse and remission is seen in CSF cells (relapse
n=17, remission, n=17) or PBMC (relapse n=31, remission n=32). *p,0.05; **p,0.01; ***p,0.001. All values were normalized to the median OND
value in CSF cells and PBMC, respectively.
doi:10.1371/journal.pone.0019138.g001
Figure 2. Box-whisker plot of VEGF-A mRNA expression in sorted peripheral blood mononuclear cell (PBMC) populations. Relative
VEGF-A mRNA expression in sorted PBMC populations from (A) untreated RRMS (n=5) and (B) RRMS treated with natalizumab (n=9) demonstrate
the highest expression of VEGF-A in the monocyte population in both groups. Monocytes were defined either as CD14
+ (A) or by gating of forward
and side scatter (B). pDC=plasmacytoid CD3
2CD304
+ cells, Treg=CD3
+CD4
+CD25
+ cells.
doi:10.1371/journal.pone.0019138.g002
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The VEGF-A gene was genotyped with six SNPs in 1114 MS
patients and 1234 controls covering haplotype blocks across the
gene and promoter sequence. This study had 80% power to detect
an odds ratio of 1.5 in the allelic test. No significant association
between single SNP alleles or genotypes or VEGF-A haplotypes
and overall risk for MS was found (Table 1). There were no gender
differences in association of genotypes to MS. Furthermore, there
was no correlation between VEGF-A alleles and VEGF-A
expression in PBMC in a subset of MS patients (n=85) and
OND controls (n=48). The sample size and the lack of detailed
and updated phenotypic information on disease course excluded
the possibility to perform association to risk of progressive MS.
Discussion
We here reproduce, in a large cohort, our previous findings that
VEGF-A mRNA expression is reduced in CSF cells of MS patients
[22]. However, the main novel finding of the present study is that
SPMS patients are characterized by a prominent decrease of
VEGF-A mRNA expression in PBMC compared to both RRMS
and controls, who display comparable levels of VEGF-A
expression. We could not demonstrate any significant correlation
to age or a number of clinical or paraclinical parameters, such as
EDSS, MSSS, disease duration or number of T2 MRI lesions,
which is in agreement with a previous study [21].These results
suggest that down regulation of VEGF-A mRNA expression in
PBMC reflects an underlying disease mechanisms that operates
specifically in progressive MS. This finding is of interest in the
context of emerging evidence that connects dysregulation of
VEGF-A to neurodegenerative processes [31]. Thus, VEGF-A
protects neurons from environmental stress and apoptosis and can
directly stimulate neurogenesis and axonal regeneration [10,31].
Targeting of the hypoxia-response element in the VEGF gene leads
Figure 3. Box-whisker plot demonstrating the VEGF-A and CD14 mRNA expression in RRMS before and after natalizumab
treatment. The effect of treatment on expression of VEGF-A in PBMC and CSF cells was studied in 19 RRMS patients prior to initiation of natalizumab
and again after 12 months of treatment. Expression of CD14 was used as a marker of monocytes. There is a robust increase in CSF cell VEGF-A mRNA
expression, (A) and a more moderate increase of CD14, (C) mRNA expression in CSF cells sampled after initiation of natalizumab treatment. In
contrast, expression of VEGF-A and CD14 is not changed in PBMC after treatment with natalizumab (B, D). *p,0.05; **p,0.01; ***p,0.001.
doi:10.1371/journal.pone.0019138.g003
Table 2. Absolute and relative number of peripheral blood
(PB) monocytes.
RRMS SPMS OND p-value
Absolute no. of PB monocytes, 0,4 0,4 0,3 ns
median (IQR) 10
9/L (0,3–0,5) (0,3–0,4) (0,3–0,4)
Relative no. of PB monocytes, 0,25 0,24 0,21 ns
median (IQR) 10
9/L (0,17–0,3) (0,18–0,53) (0,40–0,25)
No discernible difference in the absolute or relative number of peripheral blood
monocytes, as determined by peripheral blood count, are evident between
RRMS, SPMS and OND.
doi:10.1371/journal.pone.0019138.t002
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delivery of VEGF-A in a rat model of ALS delays onset of
motorneuron degeneration and prolongs survival [12,14]. The
sensitivity of motorneurons to dysregulation of VEGF-A is
interesting in light of the recent demonstration of a major loss of
spinal motorneurons also in MS [32]. Of note, Seabrook et al
demonstrated decreased levels of VEGF-A protein in rat spinal
cord tissue during EAE relapse and a reduced expression in
neurons upon immunohistochemistry [33]. Other studies on
RRMS have reported increased VEGF-A mRNA expression in
smaller groups of MS patients during relapse compared to
remission and/or controls in peripheral blood and CSF [21,23].
In addition, Su et al showed that the higher serum levels of VEGF-
A decreased within one month from relapse onset and tended to
be lower than healthy controls during remission. An increase of
VEGF-A in the initial phases of relapse is compatible with its role
as a pro-inflammatory factor that attracts monocytes and
lymphocytes, upregulates immunomodulatory adhesion molecules,
stimulates secretion of proinflammatory cytokines, and increases
blood-brain barrier permeability [22,34]. We observed a tendency
towards higher VEGF-A mRNA levels in relapse compared to
remission only in one of the studied cohorts. This discrepancy may
be related to the timing of sampling in relation to onset of relapse
symptoms or the occurrence of subclinical disease activity in the
remission group. It is known that the net effect of VEGF-A can
vary depending on the target tissue, the timing and the
concentration [35]. Neuroprotection of the ischemic brain is
critically dependent on proper dosage and may be compromised
by angiogenesis, which may explain why VEGF-A in some studies
show increased expression [19,21,36] and correlate to exacerba-
tion of disease in EAE [19,37], while others report decreased
expression [22,38]. We measured VEGF-A protein levels with
ELISA in a small subset of patients for which plasma samples were
available, revealing a non significant trend towards decreased
levels in SPMS patients compared to RRMS and controls (data
not included). Replication in larger materials is therefore needed
to demonstrate if VEGF-A expression differences also are
translated into changes in protein levels in peripheral blood.
The neurodegenerative disorders ALS and AD disease have
been associated with a genetic variation in the VEGF-A gene
(22578AA; rs699947) associated with reduced VEGF-A levels
[17,18]. We were here unable to demonstrate any haplotype
dependent association to overall risk of MS. However, the genetic
contribution of the described SNP is modest, since meta-analyses
suggest an overall 1.14–1.19 fold increased risk of ALS or AD in
subjects carrying the 22578AA genotype [17,18] and relative risks
of this magnitude are too small to be detected by our study. Larger
and better characterized clinical materials are therefore needed to
rule out a genetic association between VEGF-A and MS in general
or to SPMS in particular.
The observation that monocytes are the main cellular source of
VEGF-A expression raises the question if differences in the relative
proportion of monocytes could affect results obtained from mixed
cell populations. However, this was not the case in the periphery,
since absolute and relative monocyte numbers were similar across
the groups, in agreement with a previous study [39]. In contrast,
the finding of reduced VEGF-A expression in CSF mononuclear
cells at least in part may be explained by a relative decrease of
monocyte numbers in the CSF of MS patients compared to
controls [40]. We also studied the effect of natalizumab on VEGF-
A expression, demonstrating a robust increase in expression by this
therapy. This may be a result of a relative increase in CSF
monocyte numbers, but likely also reflects a direct or indirect
pharmacological effect of natalizumab on the phenotype of CSF
monocytes since the treatment-induced effect on expression of
CD14 was smaller.
The finding of an altered VEGF-A expression profile connected
to monocytes is interesting since accumulating evidence supports a
role for innate immune mechanisms in progressive MS. Thus,
dendritic cells of SPMS patients secrete more proinflammatory
cytokines and increased monocyte CD86 expression and IL-12
secretion is associated with transition to a progressive MS phase
[41,42]. Taken together this suggests that the transition to a
progressive disease course is connected with a change in
underlying disease mechanisms. Indeed, the observations that
clinical deterioration in SPMS generally occurs in the absence of
novel inflammatory lesions and that it does not respond to
traditional forms of immunomodulatory treatment support the
notion that other disease mechanisms are operative [43,44].
In conclusion, we here demonstrate that expression of VEGF-A
is down regulated in CSF cells irrespective of disease course, but
that solely SPMS patients display down regulated VEGF-A
expression in PBMC as compared to both RRMS and controls.
These results extend prior observations on peripheral innate
immune changes in SPMS and point towards a possible target for
future disease modulatory drugs. Also, this finding may prove to be
useful as a biomarker for SPMS, providing support for patient
management and decisions on therapeutic interventions. Further
studies are needed to address the question if dysregulated VEGF-A
expression in MS is a cause or consequence of a progressive
disease phenotype.
Supporting Information
Figure S1 Confirmatory analysis of VEGF-A mRNA
expression in CSF cells and PBMC in a separate set of
patients (study group B) composed of RRMS (n=65),
SPMS (n=20) and controls (OND; n=48). Expression of
VEGF-A mRNA is decreased in CSF cells in RRMS and SPMS
compared to OND (A). As in study group A, expression of VEGF-
A mRNA is decreased in SPMS compared to both RRMS and
controls (B). A non-significant trend towards higher expression of
VEGF-A in PBMC is evident in RRMS sampled during a relapse
(n=14) compared to remission (n=51). No significant differences
between RRMS in relapse (n=14) and remission (n=51) was
found in CSF cells. *p,0.05; **p,0.01; ***p,0.001. All values
were normalized to the median OND value in CSF cells or
PBMC.
(TIF)
Figure S2 Age span in the analyzed MS and control
groups (A). Patients with SPMS were older than both RRMS
patients and controls with OND. No significant correlation
between VEGF-A levels in CSF and age is detected in RRMS,
SPMS or the pooled MS group (B). In PBMC age is not correlated
to VEGF-A levels in the RRMS and SPMS groups. However, a
weak correlation is evident in the pooled MS group, mostly
reflecting the lower levels of VEGF-A in SPMS patients (C).
Correlation was analyzed with Spearman’s rank test and line fit
was determined with non-linear regression.
(TIF)
Table S1 Characteristics of patients and samples
included in the expression analysis.
(DOC)
Table S2 Diagnoses of the patients included in the
control group (OND).
(DOC)
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